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Abstract
Purpose To describe knee alignment in children of dif-
ferent ages with severe mucopolysaccharidosis (MPS) I
and II and the outcome of treatment with guided growth in
a patient subgroup.
Methods This is a retrospective observational study of 58
knees in 29 children with severe MPS I and II. Long-leg
standing radiographs were evaluated to determine
mechanical axis deviation, mechanical lateral distal
femoral angle and medial proximal tibial angle at different
ages throughout childhood. The change in deformity in
individual children over time is reported. 20 knees in 10
patients were treated with guided growth using eight-
plates. Radiographic measurements were recorded at the
time of plate insertion, at plate removal and at 1 year fol-
lowing removal.
Results At 8 years of age, all MPS I children and three-
quarters of MPS II children had valgus knee alignment.
There was deformity progression in two-thirds of MPS I
knees and half of MPS II knees. Guided growth corrected
the deformities. There was recurrence in most cases 1 year
after plate removal.
Conclusions Knee deformity is common in children with
severe MPS I and II. Guided growth can be considered
where there is significant and/or or progressive deformity
with the aim of halting progression and correcting existing
deformity and thus minimizing the risk of gross deformity.
Patients should be aware of the high rate of recurrence and
the need for repeat surgery.
Keywords Mucopolysaccharidoses  Knee alignment 
Guided growth
Introduction
The mucopolysaccharidoses (MPS) are a group of lysoso-
mal storage diseases characterized by the absence, reduc-
tion or malfunctioning of a lysosomal enzyme. Cellular
glycosaminoglycans (GAGs) accumulate and lead to tissue
and multi-organ dysfunction. There are different types of
MPS based on the dysfunctional enzyme. This study
focuses on MPS I and II.
The prevalence of MPS I and II is approximately 1 in
100,000 [1, 2]. MPS I is an autosomal recessive disorder
characterized by dysfunctional a-L-iduronidase leading to
accumulation of dermatan sulphate and heparan sulphate.
MPS I is recognized as a spectrum of disorders that are
split into a ‘severe’ and ‘attenuated’ form; however, they
are biochemically identical.
MPS II is an X-linked recessive disorder characterized
by dysfunctional iduronate sulphatase leading to accumu-
lation of the same GAGs as in MPS I. MPS II encompasses
a spectrum of disorders that are divided into 2 broad sub-
types—a severe form characterized by the presence of
cognitive impairment and a less severe form with no cog-
nitive impairment.
Infants with MPS I and II typically have normal
development for the first 6-12 months of life [3]. Without
treatment, children with severe MPS I usually die in their
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relatively normal life expectancy, but with significant
morbidity [4]. Without treatment, children with severe
MPS II typically die in the second decade of life [5]. Those
with the less severe form can survive until their fifth or
sixth decade [4].
A range of skeletal radiographic abnormalities known
as ‘dysostosis multiplex’ are associated with MPS I [4]
including hypoplastic vertebral bodies (resulting in
kyphosis and scoliosis), poor growth of long bones, hip
dysplasia and genu valgum [6, 7]. The rate of genu
valgum in MPS I is between 52 [8] and 70 % [9]. The
deformity is thought to originate from failure of ossifi-
cation of the lateral margin of the proximal tibial
metaphysis [6]. ‘Dysostosis multiplex’ is less dramatic
in MPS II [10]. The incidence of genu valgum is
unknown.
Haematopoietic stem cell transplantation (HSCT) is
used to treat severe MPS I [11]. Donor cells synthesise a
continuous endogenous supply of the deficient enzyme
leading to increased life expectancy and improved cogni-
tive and physical function. HCST has a mortality rate of
15 % [12]. It has been used to treat MPS II [13] but is not
usual practice. HCST has little effect on the muscu-
loskeletal system [14]. Odontoid hypoplasia shows some
improvement [15] but hip dysplasia and genu valgum
continue to progress [16, 17]. This may be due to poor
vascularity of the ground substance of musculoskeletal
tissues precluding enzyme access.
Enzyme replacement therapy (ERT) is used to treat
attenuated MPS I and severe and attenuated MPS II. In
attenuated MPS I, recombinant human a-L-iduronidase
results in short- and medium-term clinical improvements
[18]. Enzymes are unable to cross the blood–brain barrier
so provide no cognitive benefit in severe MPS I. Recom-
binant human iduronate-2-sulfatase is beneficial in severe
[19] and attenuated MPS II [20]. Although ERT can
improve joint range of motion, no improvement is seen in
hip dysplasia or genu valgum [21].
Improved life expectancy and quality of life, resulting
from HSCT and ERT, have resulted in more patients and
doctors considering surgical intervention for genu val-
gum. Surgical correction of knee deformity using guided
growth was first reported using staples [22]. More
recently, the use of eight-plates has been described [8]
but timing, indications and recurrence rates remain
unclear.
The aims of this retrospective observational study are
three-fold. Firstly, to describe knee deformity in children of
different ages with severe MPS I and II. Secondly, to
describe deformity progression in individual children, and
thirdly, to report the outcome of treatment with guided
growth in a subgroup of patients who demonstrated pro-
gressive deformity.
Materials and Methodology
All patients with MPS I or II, who were treated at our
institution between January 2004 and December 2014, with
a minimum of one full-length standing leg X-ray were
included in the study. X-rays were standardised with
patellae facing forward, a level pelvis and a measurement
ball on each film.
A total of 29 children (58 legs) were included in the
study—17 children with severe MPS I and 12 children with
severe MPS II. There were 10 males and 7 females in the
MPS I group. The MPS II group was entirely male. All
MPS I patients had received HSCT (2/17 subsequently
received ERT). All MPS II patients were receiving ERT.
Treatments were started prior to radiographic assessment
of knee alignment.
The Picture Archiving and Communication System was
used to determine the alignment of each knee by measuring
mechanical axis deviation (MAD). MAD was classified as
passing through one of four zones. A positive value indi-
cated a valgus knee and a negative value indicated a varus
knee. Zones were calculated in relation to the width of the
tibial plateau (Fig. 1). The source of knee deformity was
determined by measuring the mechanical lateral distal
femoral angle (mLDFA) and the medial proximal tibial
angle (MPTA).
The mean and range of each radiographic measure is
reported for X-rays between the ages of 2 and 9 years for
MPS I and between the ages of 4 and 13 years for MPS II
(or within 6 months of each time point). No child with
MPS I had a limb alignment X-ray performed under the age
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Fig. 1 Radiograph showing the zones of the knee. Zone 0 is a
vertical line through the central point of the tibial plateau (thick white
line). Each half of the tibial plateau is divided into two. Zone 1 is
located next to the central line and zone 2 is more peripheral. A
vertical line is drawn on either side of the knee at a distance equal to
the width of the tibial hemi-plateau. Zone 3 lies between the tibial
plateau and this line and zone 4 lies outside this line. The mechanical
axis deviation zones have positive values in a valgus knee and
negative values in a varus knee
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of 2 years and no child with MPS II had an X-ray per-
formed under the age of 4 years. Corrective surgery was
performed at a mean age of 9 years in MPS I and 13 years
in MPS II. Radiographs after the implementation of guided
growth techniques are not reported in this part of the study
as they would not be representative of natural progression.
In total, 67 radiographs (134 knees) in children with MPS I
and 37 radiographs (74 knees) in children with MPS II
were evaluated.
To assess disease progression in individual children,
only those with a minimum of 3 X-rays prior to any sur-
gical intervention were included for analysis. There were
12 children with MPS I (24 knees) and 8 children with
MPS II (16 knees). Details of the number and timing of
X-rays are shown in Table 1. Radiographic findings on the
initial X-ray were compared to those on the final X-ray. To
assess the rate of disease progression, the change in
radiographic appearance was divided by the time taken for
the change to occur.
A total of 10 children (7 with MPS I and 3 with MPS II)
were treated with guided growth using Orthofix eight-
plates. Indications for surgery included a MAD through
zone 3 or higher or a MAD through zone 2 together with
evidence of deformity progression. The origin of the knee
deformity was established from the mLDFA and MPTA.
Eight-plates were inserted into the proximal tibia and/or the
distal femur as appropriate. Radiographic measurements at
the time of eight-plate insertion, at eight-plate removal and
at 1 year following eight-plate removal are reported.
Results
Knee alignment in children of different ages
The MAD, mLDFA and MPTA were assessed in 29 chil-
dren (58 legs) at different ages. Results are shown in
Figs. 2, 3 and 4, respectively, highlighting the differences
between MPS I and II patients.
Deformity progression in individual children
Deformity progression over time was assessed in 20 chil-
dren (40 knees). Results are shown in Table 2. In knees
with progressive deterioration in mechanical axis devia-
tion, the mean rate of change in MPS I was 0.51 zones/year
(range 0.20–1.10) and in MPS II was 0.59 zones/year
(range 0.33–1.54).
Results of treatment with guided growth
A total of 10 children (20 knees) were treated with guided
growth. The plates were removed in 6 cases (12 knees);
details are given in Table 3. There was correction of
deformity to MAD zone –1, 0 or 1 in all cases. The mean
time plates remained in situ was 1.6 years. Deformity
recurred in 3 children (6 knees) following plate removal.
Table 1 Number and timing of
full-length leg X-rays used to
assess knee alignment over time
MPS I MPS II
Number of knees evaluated 24 16
Mean number of knee X-rays taken (range) 4.8 (3-12) 3.6 (3-5)
Mean age at first X-ray (range) 6.9 years (2.3–10.4) 7.5 years (4.2–13.8)
Mean age at final X-ray (range) 10.0 years (5.2–13.0) 11.2 years (5.8–16.2)





















































Fig. 2 a Mechanical axis deviation in children with MPS I at
different ages. Grey dot represents the mean value and the black line
represents the range. b Mechanical axis deviation in children with
MPS II at different ages. Grey dot represents the mean value and the
black line represents the range
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Correction was maintained in one patient (2 legs) who was
skeletally mature at the time of plate removal. Details of
the 4 children (8 knees) where eight-plates remained in situ
are given in Table 4. The MAD is showing improvement in
all cases.
Discussion
Knee deformity is common in children with MPS types I
and II. Knee alignment in MPS has previously been
described using the tibio-femoral angle only [8, 22].
Children with MPS have a high incidence of hip dysplasia
[8] and therefore a normal tibio-femoral angle may not
correlate with a normal mechanical axis. It is for this rea-
son that MAD was used in this study.
In MPS I, a gradual increase in the mean MAD was seen
in children of increasing age. This trend was less clear in
children with MPS II. All MPS I children[8 years had
valgus knee alignment. In MPS II children, 75 %[8 years
had valgus knee alignment, 21 % had varus alignment and
4 % had neutral alignment. MPS I children tended to have
greater knee deformity than MPS II children of the same
age. No MPS II child had MAD through zone 4, although
seven MPS I children did.
With increasing age, there was no change in the mLDFA
in children with MPS I and MPS II. A valgus distal femur
(mLDFA B 85) was more common in MPS I and a varus
distal femur (mLDFA C 91) was more common in MPS
II.
In MPS I children of increasing age, there was a steady
increase in the mean MPTA. There was no clear trend in
MPS II. All MPS I children[8 years had a valgus proximal









































Fig. 3 a Mechanical lateral distal femoral angle (mLDFA) in
children with MPS I at different ages. Grey dot represents the mean
value and the black line represents the range. The heavy horizontal
line highlights the normal value of 88. b Mechanical lateral distal
femoral angle (mLDFA) in children with MPS II at different ages.
Grey dot represents the mean value and the black line represents the



























Fig. 4 aMedial proximal tibial angle (MPTA) in children with MPS
I at different ages. Grey dot represents the mean value and the black
line represents the range. The heavy horizontal line represents the
normal value of 88. b Medial proximal tibial angle (MPTA) in
children with MPS II at different ages. Grey dot represents the mean
value and the black line represents the range. The heavy horizontal
line represents the normal value of 88
Table 2 Change in mechanical axis deviation in individual children
with time
Change in MAD with time MPS I MPS II
Deteriorates 15/24 (63 %) 8/16 (50 %)
Remains constant 9/24 (37 %) 6/16 (38 %)
Improves 0/24 (0 %) 2/16 (12 %)
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had a valgus proximal tibia and 31 % had neutral align-
ment. No child of any age with MPS I or II had a varus
proximal tibia (mMPTA B 85).
In individual children, the MAD worsened over time in
approximately two-thirds of MPS I knees and half of MPS
II knees. On average, it took 2 years for the MAD to
progress one zone. In MPS I, the fastest deforming knee
took 1 year to progress one MAD zone. In MPS II, the
fastest deforming knee took \8 months to progress one
MAD zone.
Guided growth using eight-plates adequately corrected
knee alignment in all cases. Recurrence of deformity was
seen in three of four (75 %) cases at 1 year following plate
removal. Correction was maintained in 1 case. This patient
was skeletally mature at the time of eight-plate removal.
X-rays of a ‘typical’ MPS I patient following eight-plate
insertion and removal are shown in Fig. 5.
We believe there are 2 advantages to treating skeletally
immature children with guided growth, despite deformity
recurrence following plate removal. Firstly, deformity
progression is delayed. The plates remain in situ for a mean
of 1.6 years and it takes 1 year for deformity to recur
following plate removal. Thus, there is no deformity pro-
gression for over 2 years. In this time period, deformity
progression of over one MAD zone (based on our results)
would be expected if the plates had not been inserted.
Secondly, deformity is not allowed to reach a ‘critical’
level that could limit function. The correlation between
knee deformity and function in children with MPS requires
further research. Recurrent deformity can be treated by
reapplication of the guided growth principles.
Knee deformity in children with MPS has previously
been reported. Stoop et al. [7] described genu valgum in a
series of 13 knees in 13 children with MPS I. They reported




















MAD Zone at present
time with eight-plates
in-stu
7 I M Right Tibia 8.8 2.1 3 2
Left Tibia 8.8 2.1 4 2
8 I M Right Tibia 8.6 0.3 4 3
Left Tibia 8.6 0.3 4 3
9 I F Right Femur/tibia 9.1 0.7 3 0
Left Femur/tibia 9.1 0.7 3 0
10 II M Right Tibia 13.0 1.1 3 2
Left Tibia 13.0 1.1 3 0

































1 I F Right Tibia/femur 6.5 8.0 1.5 4 0 4
Left Tibia/femur 6.5 8.0 1.5 4 1 3
2 I F Right Femur 7.3 8.7 1.4 3 –1 3
Left Femur 7.3 8.7 1.4 4 1 3
3 I F Right Tibia/femur 9.6 10.7 1.1 3 –1 2
Left Tibia/femur 9.6 10.7 1.1 3 0 1
4 II M Right Tibia 11.8 13.5 1.7 2 –1 a
Left Tibia 11.8 13.5 1.7 3 1 a
5 I M Right Tibia 10.7 12.4 1.7 2 0 a
Left Tibia 10.7 12.4 1.7 4 1 a
6 II M Right Tibia 14.2 16.2 2.0 2 0 0
Left Tibia 14.2 16.2 2.0 3 1 1
a Insufficient time elapsed to provide figures for patients 4 and 5
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a high MPTA in 12/13 knees. A similar result was found in
our series. Stoop et al. did not report overall knee align-
ment or the femoral contribution to knee deformity. They
reported a maximum MPTA value between the ages of 3
and 5 years. This differs from our study where the mean
MPTA continued to increase until at least 9 years of age.
Treatment with guided growth in MPS has previously
been reported. Taylor et al. [22] reported 5 patients with
MPS I treated with stapling of the medial tibial epiphysis.
The tibio-femoral angle corrected from a mean of 17 to
10. The contribution of the distal femur to the knee
deformity and recurrence rates following staple removal
are not reported.
Odunusi et al. [8] described treatment with guided
growth in 8 valgus knees in children with MPS I using
staples. There was complete correction of deformity in 2
knees and incomplete correction in 6 knees. Deformity
recurred in 5 cases after staple removal and there was
incomplete follow-up in 1 case. There was no recurrence in
2 knees. Both these patients were near skeletal maturity at
the time of staple removal (age 14 and 15 years, respec-
tively). This is the same as our study where there was no
recurrence in one patient who had reached skeletal maturity
prior to plate removal.
There are two possible strategies for treatment with
guided growth. The first strategy involves performing
surgery when knee alignment becomes ‘unacceptable’,
e.g., when the MAD progresses to zone 3 on the assump-
tion that gross deformity does alter gait mechanics and is
associated with discomfort. Early treatment would correct
the MAD and knee alignment would be maintained within
specified limits to limit pain and maintain function. A
disadvantage is that a child may require two or three sur-
gical interventions during their childhood to achieve neu-
tral limb alignment at skeletal maturity.
A second strategy would be to delay treatment with
guided growth until the child is nearing skeletal maturity in
an attempt to achieve normal knee alignment at the time
skeletal maturity is reached. An advantage of this strategy
is that it requires a single operation. A disadvantage is that
a child may develop severe deformity that limits function;
correction of a MAD in zone 4 may not occur so reliably as
in a younger child particularly as the rate of deformity
correction varies between individuals, so it would be dif-
ficult to estimate the time of plate insertion. If plates were
inserted too early they would need to be removed with the
risk of deformity recurrence. If the plates were inserted too
late there would be under-correction of the deformity.
Our study has several strengths. It has a large study
population for such a rare condition, there are several
standing long-leg X-rays for many patients allowing dis-
ease progression to be reported over time and 3 important
aspects of knee alignment have been reported (MAD,
mLDFA and MPTA). This study also has weaknesses. It
was performed retrospectively and is based solely on
radiographic measurements that may not correlate to
patient symptoms. Radiographs were taken at different
ages and at different time intervals. Deformity progression
was assessed in individual knees over a mean time period
of 3 years. Studies with longer follow-up are necessary to
assess progression throughout childhood. For the treatment
arm of this study, only 8 knees underwent 1-year follow-up
following plate removal, making this a case series rather
than a true study. Nevertheless, we have shown that guided
growth has the potential to improve significant deformity
and maintain it in the short term.
Medical treatments for MPS I and MPS II [23, 24] have
improved life expectancy and quality of life, resulting in
more patients and doctors considering guided growth to
correct knee alignment. When considering surgery, it is
Fig. 5 X-rays showing ‘typical’ improvement in knee alignment with insertion of eight-plates and recurrence of deformity following plate
removal
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important to treat the source of the deformity (tibia, femur
or both). Surgery should only be considered if the defor-
mity is sufficiently severe or shows evidence of progres-
sion. This study shows that not all deformities progress in
the medium-term. Patients should be aware of the high rate
of deformity recurrence following plate removal and the
need for further surgery in the future. It remains to be seen
whether guided growth treatments can deliver a straight leg
at skeletal maturity in children with MPS I and MPS II.
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